Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Minerva Neurosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FDA CONFIRMS REQUIREMENT FOR CONFIRMATORY STUDY OF ROLUPERIDONE FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

MINERVA NEUROSCIENCES PROVIDES BUSINESS UPDATES AND SECOND QUARTER FINANCIAL RESULTS

BURLINGTON, MASS., MAY 13, 2025 (GLOBE NEWSWIRE) -- MINERVA NEUROSCIENCES, INC.(NASDAQ: NERV), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF THERAPIES TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS, TODAY REPORTED BUSINESS UPDATES AND FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2025 ENDED ON MARCH 31, 2025.

MINERVA NEUROSCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

BURLINGTON, MASS., FEB. 25, 2025 (GLOBE NEWSWIRE) -- MINERVA NEUROSCIENCES, INC.(NASDAQ: NERV), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF THERAPIES TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS, TODAY REPORTED BUSINESS UPDATES AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2024.

MINERVA NEUROSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2024 FINANCIAL RESULTS AND BUSINESS UPDATES

BURLINGTON, MASS., NOV. 05, 2024 (GLOBE NEWSWIRE) -- MINERVA NEUROSCIENCES, INC. (NASDAQ: NERV), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF THERAPIES TO TREAT CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, TODAY REPORTED BUSINESS UPDATES AND FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2024 ENDING SEPTEMBER 30, 2024.

MINERVA NEUROSCIENCES REPORTS THIRD QUARTER 2024FINANCIAL RESULTS AND BUSINESS UPDATES

BURLINGTON, MASS., MAY 01, 2024 (GLOBE NEWSWIRE) -- MINERVA NEUROSCIENCES, INC. (NASDAQ: NERV), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF THERAPIES TO TREAT CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, TODAY REPORTED BUSINESS UPDATES AND FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2024 ENDING MARCH 31, 2024.

MINERVA NEUROSCIENCES REPORTS FIRST QUARTER 2024FINANCIAL RESULTS AND BUSINESS UPDATES

BURLINGTON, MASS., FEB. 22, 2024 (GLOBE NEWSWIRE) -- MINERVA NEUROSCIENCES, INC.(NASDAQ: NERV), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF THERAPIES TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS, TODAY REPORTED BUSINESS UPDATES AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2023.

MINERVA NEUROSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023FINANCIAL RESULTS AND BUSINESS UPDATES

BURLINGTON, MASS., NOV. 07, 2023 (GLOBE NEWSWIRE) -- MINERVA NEUROSCIENCES, INC.(NASDAQ: NERV), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF THERAPIES TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS, TODAY REPORTED BUSINESS UPDATES AND FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2023.

MINERVA NEUROSCIENCES REPORTS 2023 THIRD QUARTERFINANCIAL RESULTS AND BUSINESS UPDATES

BURLINGTON, MASS., AUG. 01, 2023 (GLOBE NEWSWIRE) -- MINERVA NEUROSCIENCES, INC.(NASDAQ: NERV), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF THERAPIES TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS, TODAY REPORTED BUSINESS UPDATES AND FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2023.

MINERVA NEUROSCIENCES REPORTS 2023 SECOND QUARTER FINANCIAL RESULTS AND BUSINESS UPDATES

BURLINGTON, MASS., JUNE 28, 2023 (GLOBE NEWSWIRE) -- MINERVA NEUROSCIENCES, INC.(NASDAQ: NERV), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF THERAPIES TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS, TODAY ANNOUNCED THAT IT HAS AGREED TO SELL AN AGGREGATE OF 1,425,000 SHARES OF ITS COMMON STOCK AT A PURCHASE PRICE OF $10 PER SHARE AND PRE-FUNDED WARRANTS TO PURCHASE AN AGGREGATE OF 575,575 SHARES OF ITS COMMON STOCK AT A PURCHASE PRICE OF $9.99 PER PRE-FUNDED WARRANT, TO BOEHRINGER INGELHEIM, A GLOBAL BIOPHARMACEUTICAL COMPANY WITH A GROWING MENTAL HEALTH PIPELINE THAT INCLUDES SCHIZOPHRENIA, AND FEDERATED HERMES KAUFMANN FUNDS IN A PRIVATE INVESTMENT IN PUBLIC EQUITY (THE PIPE) FINANCING. MINERVA EXPECTS THAT THE GROSS PROCEEDS FROM THE PIPE WILL BE APPROXIMATELY $20 MILLION, BEFORE DEDUCTING PIPE-RELATED EXPENSES PAYABLE BY MINERVA. MINERVA INTENDS TO USE THE NET PROCEEDS FROM THE PIPE TO SUPPORT POTENTIAL REGULATORY APPROVAL IN THE U.S., COMMERCIALIZATION ACTIVITIES AND MARKET LAUNCH OF ROLUPERIDONE, WHICH IS BEING DEVELOPED FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA.

MINERVA NEUROSCIENCES ANNOUNCES $20 MILLION IN PRIVATE PLACEMENT PRICED AT A PREMIUM TO MARKET

BURLINGTON, MASS., MAY 15, 2023 (GLOBE NEWSWIRE) -- MINERVA NEUROSCIENCES, INC.(NASDAQ: NERV), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF THERAPIES TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS, TODAY REPORTED BUSINESS UPDATES AND FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2023.

MINERVA NEUROSCIENCES REPORTS 2023 FIRST QUARTERFINANCIAL RESULTS AND BUSINESS UPDATES

FDA CONFIRMS ACCEPTANCE OF THE FILING OF THE NDA FOR ROLUPERIDONE APPLICATION HAS BEEN GRANTED A STANDARD REVIEW FDA HAS ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE OF FEBRUARY 26, 2024 BURLINGTON, MASS., MAY 10, 2023 (GLOBE NEWSWIRE) -- MINERVA NEUROSCIENCES, INC. (NASDAQ: NERV), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF THERAPIES TO TREAT CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, TODAY ANNOUNCED THAT ON MAY 8, 2023, IT RECEIVED CONFIRMATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) THAT THE COMPANY'S NEW DRUG APPLICATION (NDA) FOR ROLUPERIDONE FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA HAS BEEN FILED IN ACCORDANCE WITH THE RECENT APPEAL GRANTED LETTER DATED APRIL 27, 2023 AND ASSIGNED A STANDARD REVIEW CLASSIFICATION.

Minerva Neurosciences, Inc.

NERV

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Minerva Neurosciences, Inc.

NERV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NERV